Choose Your Country or Region

Semaglutide Sodium

Name: Semaglutide Sodium
Brand: Selleck Chemicals
SKU: S9697

Synonyms: Rybelsus, Ozempic, NN9535, OG217SC, NNC 0113-0217

Catalog No.S9697 Purity: 99.95%

Semaglutide Sodium (Rybelsus, Ozempic, NN9535, OG217SC, NNC 0113-0217), a long-acting glucagon-like peptide 1 (GLP-1) analogue, is a GLP-1 receptor agonist with the potential for the treatment of type 2 diabetes mellitus (T2DM).

Semaglutide Sodium Chemical Structure

CAS: 910463-68-2(free base)

Purity & Quality Control

Batch: Purity: 99.95%

99.95

Related compound libraries

Choose Selective Glucagon Receptor Inhibitors

Biological Activity

Description

Targets

GLP-1 receptor ^[1]

In vitro
In vitro	Semaglutide is selected as the optimal once weekly candidate. Semaglutide has two amino acid substitutions compared to human GLP-1 (Aib8, Arg34) and is derivatized at lysine 26. The GLP-1R affinity of semaglutide (0.38 ± 0.06 nM) is three-fold decreased compared to liraglutide, whereas the albumin affinity is increased.^[2]
Cell Research	Cell lines	BHK cells
	Concentrations	0.01 pM - 0.1 μM
	Incubation Time	3 h
	Method	Frozen aliquots of BHK cells that express both the hGLP-1R and CRE firefly luciferase (clone FCW467-12A/KZ10-1) are thawed, washed twice in PBS, and suspended in assay buffer. Cells are plated out into 96-well plates at 5000 cells/well in a volume of 50 μL. Compounds to be tested are diluted in assay buffer and a 50 μL aliquot transferred to the plate containing the cells to reach final assay concentrations of 1 × 10⁻¹⁴ − 1 × 10⁻⁷ M. The plate is incubated for 3 h at 5% CO₂ at 37 °C. The plate was allowed to stand at room temperature for 15 min prior to adding 100 μL of steadylite plus reagent. The plate is covered to protect it from light and shaken at room temperature for 30 min. The plate is read in a TopCount NXT instrument.

In Vivo
In vivo	The plasma half-life is 46.1 h in mini-pigs following i.v. administration, and semaglutide has an MRT of 63.6 h after s.c. dosing to mini-pigs.^[2]

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2024-01-11)
NCT05714683	Not yet recruiting	Diabetes Mellitus Type 2	Novo Nordisk A/S	December 31 2024	--
NCT06015893	Recruiting	Addiction\|Alcohol Use Disorder	National Institute on Drug Abuse (NIDA)\|National Institutes of Health Clinical Center (CC)	January 12 2024	Phase 2
NCT06073184	Not yet recruiting	Endometrial Cancer\|Atypical Hyperplasia	University Health Network Toronto	January 2024	Phase 2
NCT05689372	Not yet recruiting	Diabetes Mellitus Type 2	Novo Nordisk A/S	December 31 2023	--
NCT06003153	Not yet recruiting	Genetic Predisposition\|Metabolic Diseases\|Type 2 Diabetes	Massachusetts General Hospital\|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	October 1 2023	Phase 4

References

Chemical lnformation & Solubility

Molecular Weight	4113.58(free base)	Formula	C₁₈₇H₂₉₁N₄₅O₅₉
CAS No.	910463-68-2(free base)	SDF	--
Storage (From the date of receipt)	3 years -20°C powder	Storage of Stock Solutions Aliquot the stock solutions to avoid repeated freeze-thaw cycles	1 year-80°Cin solvent
Storage (From the date of receipt)	3 years -20°C powder		1 month-20°Cin solvent

In vitro
Batch:

4-Methylpyridine : 4 mg/mL

Water : Insoluble

Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.

In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):